Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) EBT (2016 - 2025)

Macrogenics (MGNX) has disclosed EBT for 14 consecutive years, with -$14.9 million as the latest value for Q4 2025.

  • Quarterly EBT fell 3.14% to -$14.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$77.0 million through Dec 2025, down 12.01% year-over-year, with the annual reading at -$75.3 million for FY2025, 14.04% down from the prior year.
  • EBT for Q4 2025 was -$14.9 million at Macrogenics, down from $16.8 million in the prior quarter.
  • The five-year high for EBT was $56.3 million in Q3 2024, with the low at -$66.6 million in Q1 2022.
  • Average EBT over 5 years is -$32.0 million, with a median of -$41.0 million recorded in 2021.
  • The sharpest move saw EBT plummeted 2583.69% in 2021, then soared 258.61% in 2024.
  • Over 5 years, EBT stood at -$58.2 million in 2021, then surged by 120.58% to $12.0 million in 2022, then crashed by 511.87% to -$49.4 million in 2023, then soared by 70.67% to -$14.5 million in 2024, then decreased by 3.14% to -$14.9 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$14.9 million, $16.8 million, and -$36.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.